{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:48:48Z","timestamp":1790142528408,"version":"4.0.1"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.breast.2017.10.014","type":"journal-article","created":{"date-parts":[[2017,11,20]],"date-time":"2017-11-20T07:17:41Z","timestamp":1511162261000},"page":"126-133","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":96,"special_numbering":"C","title":["Targeting FGFR pathway in breast cancer"],"prefix":"10.1016","volume":"37","author":[{"given":"J.","family":"Perez-Garcia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Mu\u00f1oz-Couselo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Soberino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Racca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2017.10.014_bib1","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"Perou","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.breast.2017.10.014_bib2","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.breast.2017.10.014_bib3","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa1113216","article-title":"Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.breast.2017.10.014_bib4","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.breast.2017.10.014_bib5","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.breast.2017.10.014_bib6","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.breast.2017.10.014_bib7","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.breast.2017.10.014_bib8","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","article-title":"Ribociclib as first-line therapy for HR-positive, advanced breast cancer","volume":"375","author":"Hortobagyi","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.breast.2017.10.014_bib9","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1056\/NEJMoa064320","article-title":"Lapatinib plus capecitabine for HER2-positive advanced breast cancer","volume":"355","author":"Geyer","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.breast.2017.10.014_bib10","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S1470-2045(15)00551-3","article-title":"Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"17","author":"Chan","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2017.10.014_bib11","doi-asserted-by":"crossref","first-page":"5218","DOI":"10.1158\/1078-0432.CCR-17-0754","article-title":"MONARCH 1, a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR+\/HER2- metastatic breast cancer","volume":"23","author":"Dickler","year":"2017","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.breast.2017.10.014_bib12","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","article-title":"MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+\/HER2- advanced breast cancer who had progressed while receiving endocrine therapy","volume":"35","author":"Sledge","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2017.10.014_bib13","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nrc2780","article-title":"Fibroblast growth factor signalling: from development to cancer","volume":"10","author":"Turner","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.breast.2017.10.014_bib14","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nrc.2017.8","article-title":"Advances and challenges in targeting FGFR signalling in cancer","volume":"17","author":"Babina","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.breast.2017.10.014_bib15","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1158\/1541-7786.MCR-10-0168","article-title":"Roles of fibroblast growth factor receptors in carcinogenesis","volume":"8","author":"Haugsten","year":"2010","journal-title":"Mol Canc Res"},{"key":"10.1016\/j.breast.2017.10.014_bib16","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s00018-010-0576-3","article-title":"Biology of FGFRL1, the fifth fibroblast growth factor receptor","volume":"68","author":"Trueb","year":"2011","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.breast.2017.10.014_bib17","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.cytogfr.2005.01.001","article-title":"Cellular signaling by fibroblast growth factor receptors","volume":"16","author":"Eswarakumar","year":"2005","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.breast.2017.10.014_bib18","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1158\/1078-0432.CCR-14-3212","article-title":"The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing","volume":"22","author":"Helsten","year":"2016","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.breast.2017.10.014_bib19","doi-asserted-by":"crossref","first-page":"R23","DOI":"10.1186\/bcr1665","article-title":"FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis","volume":"9","author":"Elbauomy Elsheikh","year":"2007","journal-title":"Breast Canc Res"},{"key":"10.1016\/j.breast.2017.10.014_bib20","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.1013","article-title":"FGFR gene amplification and response to endocrine therapy in metastatic hormone receptor positive (HR+) breast cancer","volume":"35","author":"Drago","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2017.10.014_bib21","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/annonc\/mdt419","article-title":"Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors","volume":"25","author":"Dienstmann","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2017.10.014_bib22","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1038\/onc.2009.34","article-title":"Co-amplified genes at 8p12 and 11q13 in breast tumors cooperate with two major pathways in oncogenesis","volume":"28","author":"Kwek","year":"2009","journal-title":"Oncogene"},{"key":"10.1016\/j.breast.2017.10.014_bib23","doi-asserted-by":"crossref","first-page":"6652","DOI":"10.1158\/1078-0432.CCR-06-1164","article-title":"FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas","volume":"12","author":"Reis-Filho","year":"2006","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.breast.2017.10.014_bib24","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1038\/onc.2009.489","article-title":"Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets","volume":"29","author":"Turner","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.breast.2017.10.014_bib25","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1016\/j.celrep.2016.02.023","article-title":"Large-scale profiling of kinase dependencies in cancer cell lines","volume":"14","author":"Campbell","year":"2016","journal-title":"Cell Rep"},{"key":"10.1016\/j.breast.2017.10.014_bib26","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/ijc.2910610205","article-title":"Expression of FGF and FGF receptor genes in human breast cancer","volume":"61","author":"Penault-Llorca","year":"1995","journal-title":"Int J Cancer"},{"key":"10.1016\/j.breast.2017.10.014_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10549-015-3301-y","article-title":"Rationale for targeting fibroblast growth factor receptor signaling in breast cancer","volume":"150","author":"Andre","year":"2015","journal-title":"Breast Canc Res Treat"},{"key":"10.1016\/j.breast.2017.10.014_bib28","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1158\/2159-8290.CD-13-0050","article-title":"Identification of targetable FGFR gene fusions in diverse cancers","volume":"3","author":"Wu","year":"2013","journal-title":"Canc Discov"},{"key":"10.1016\/j.breast.2017.10.014_bib29","doi-asserted-by":"crossref","first-page":"3693","DOI":"10.1158\/1078-0432.CCR-13-0190","article-title":"Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer","volume":"19","author":"Andre","year":"2013","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.breast.2017.10.014_bib30","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s10549-009-0677-6","article-title":"Amplification of fibroblast growth factor receptor-1 in breast cancer and the effects of brivanib alaninate","volume":"123","author":"Shiang","year":"2010","journal-title":"Breast Canc Res Treat"},{"key":"10.1016\/j.breast.2017.10.014_bib31","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1158\/0008-5472.CAN-09-3746","article-title":"FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer","volume":"70","author":"Turner","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.breast.2017.10.014_bib32","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.537","article-title":"Prognostic and therapeutic implications of fibroblast growth factor receptors (FGFRs) 1 and 2 gene amplifications in patients (pts) with advanced breast cancer (ABC)","volume":"34","author":"Racca","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2017.10.014_bib33","series-title":"Proceedings: AACR 108th annual meeting","article-title":"Gain-of-function kinase library screen identifies FGFR1 amplification as a mechanism of resistance to antiestrogens and CDK4\/6 inhibitors in ER+ breast cancer","author":"Formisano","year":"2017"},{"key":"10.1016\/j.breast.2017.10.014_bib34","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.1158\/1078-0432.CCR-16-2287","article-title":"HER2-Overexpressing breast cancers amplify FGFR signaling upon acquisition of resistance to dual therapeutic blockade of HER2","volume":"23","author":"Hanker","year":"2017","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.breast.2017.10.014_bib35","doi-asserted-by":"crossref","first-page":"R115","DOI":"10.1530\/ERC-12-0060","article-title":"Fibroblast growth factor receptors in breast cancer: expression, downstream effects, and possible drug targets","volume":"19","author":"Tenhagen","year":"2012","journal-title":"Endocr Relat Canc"},{"key":"10.1016\/j.breast.2017.10.014_bib36","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1158\/0008-5472.CAN-10-2700","article-title":"E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models","volume":"71","author":"Bello","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.breast.2017.10.014_bib37","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1093\/annonc\/mdu390","article-title":"Phase I\/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors","volume":"25","author":"Soria","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2017.10.014_bib38","first-page":"225","article-title":"Thyroid dysfunction in patients treated with sunitinib or sorafenib","volume":"10","author":"Clemons","year":"2012","journal-title":"Clin Genitourin Canc"},{"key":"10.1016\/j.breast.2017.10.014_bib39","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1200\/JCO.2016.67.2048","volume":"35","author":"Nogova","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2017.10.014_bib40","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1200\/JCO.2014.60.7341","article-title":"Phase I dose-escalation study of JNJ-42756493, an oral Pan-Fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors","volume":"33","author":"Tabernero","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2017.10.014_bib41","series-title":"Proceedings: AACR 104th annual meeting","article-title":"Results of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), in patients with advanced solid tumors","author":"Andre","year":"2013"},{"key":"10.1016\/j.breast.2017.10.014_bib42","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.2508","article-title":"Phase II multicenter proof of concept study of AZD4547 in FGFR amplified tumours","volume":"33","author":"Smyth","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2017.10.014_bib43","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1158\/2159-8290.CD-15-1246","article-title":"High-level clonal FGFR amplification and response to FGFR inhibition in a translational clinical trial","volume":"6","author":"Pearson","year":"2016","journal-title":"Canc Discov"},{"key":"10.1016\/j.breast.2017.10.014_bib44","doi-asserted-by":"crossref","first-page":"4356","DOI":"10.1158\/1078-0432.CCR-14-3357","article-title":"FGFR1 expression levels predict BGJ398 sensitivity of FGFR1-dependent head and neck squamous cell cancers","volume":"21","author":"Goke","year":"2015","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.breast.2017.10.014_bib45","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1158\/1078-0432.CCR-13-3060","article-title":"FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies","volume":"20","author":"Wynes","year":"2014","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.breast.2017.10.014_bib46","doi-asserted-by":"crossref","first-page":"6130","DOI":"10.1158\/1078-0432.CCR-11-0659","article-title":"Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis","volume":"17","author":"Lieu","year":"2011","journal-title":"Clin Canc Res"},{"issue":"6","key":"10.1016\/j.breast.2017.10.014_bib47","first-page":"114","article-title":"Phase 1 study of ODM-203, a selective dual FGFR\/VEGFR inhibitor, in patients with advanced solid tumours","volume":"27","author":"Rodon","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2017.10.014_bib48","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13058-017-0807-8","article-title":"Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2- breast cancer that had progressed during or after prior endocrine therapy","volume":"19","author":"Musolino","year":"2017","journal-title":"Breast Canc Res"},{"key":"10.1016\/j.breast.2017.10.014_bib49","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1200\/JCO.2014.60.1971","article-title":"Correlative analysis of genetic alterations and everolimus benefit in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from BOLERO-2","volume":"34","author":"Hortobagyi","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2017.10.014_bib50","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.2500","article-title":"Phase Ib study of BGJ398 in combination with BYL719 in patients (pts) with select advanced solid tumors","volume":"34","author":"Hyman","year":"2016","journal-title":"J\u00a0Clin Oncol"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977617306094?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977617306094?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:39:14Z","timestamp":1760776754000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977617306094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":50,"alternative-id":["S0960977617306094"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2017.10.014","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting FGFR pathway in breast cancer","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2017.10.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}